The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features.

Trial Profile

The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Quetiapine (Primary) ; Citalopram; Escitalopram; Sertraline
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Feb 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 19 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top